Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects
- PMID: 7551371
- DOI: 10.1164/ajrccm.152.4.7551371
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects
Abstract
The leukotrienes are known bronchoactive agonists with potential proinflammatory effects that may be involved in mediating airway hyperresponsiveness. We investigated the effects of zileuton, an inhibitor of 5-lipoxygenase (5-LO), on airway responsiveness to cold, dry air in patients with moderate asthma. A group of 10 asthmatic patients underwent cold, dry air hyperventilation challenge; challenges were performed before drug treatment and 1 to 10 d after the completion of treatment with study drugs. The cold air minute ventilation required to cause a 15% decrease in FEV1 (PD15 VE) increased by 58% compared with the response before treatment, 1 to 10 d after the completion of 13 wk of treatment with zileuton. The geometric mean (geometric mean/SEM and geometric mean x SEM) PD15 VE increased from 24.5 (20.4, 29.5) L/min to 38.8 (34.7, 43.7) L/min (p = 0.01). Zileuton treatment inhibited 5-LO as measured ex vivo by ionophore-stimulated LTB4 levels in whole blood. In four of seven subjects, LTB4 levels before zileuton ingestion fell from 110.88 +/- 25.42 to 5.40 +/- 1.95 ng/ml 2 h post-zileuton dosing (p = 0.02, pre- versus 2 h postzileuton ingestion). Consistent with the short half-life of zileuton, 6 h postzileuton dosing the ionophore-stimulated, LTB4 levels in whole blood had increased to 89.68 +/- 35.54 ng/ml (p = 0.41, pre- versus 6 h postzileuton ingestion). Based on the first-order kinetics of zileuton, its effect on 5-LO activity should have been dissipated less than 16 h postingestion. Thus, chronic zileuton treatment decreased airway hyperresponsiveness as determined by reactivity to cold, dry air.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1187-94. doi: 10.1164/ajrccm.157.4.9707089. Am J Respir Crit Care Med. 1998. PMID: 9563738 Clinical Trial.
-
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.N Engl J Med. 1990 Dec 20;323(25):1740-4. doi: 10.1056/NEJM199012203232505. N Engl J Med. 1990. PMID: 2247106 Clinical Trial.
-
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.Eur Respir J. 1997 Dec;10(12):2749-53. doi: 10.1183/09031936.97.10122749. Eur Respir J. 1997. PMID: 9493655 Clinical Trial.
-
[5-lipoxygenase inhibitors in asthma therapy].Nihon Rinsho. 1996 Nov;54(11):3040-4. Nihon Rinsho. 1996. PMID: 8950951 Review. Japanese.
-
Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway.Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):319-20. doi: 10.1159/000237013. Int Arch Allergy Immunol. 1995. PMID: 7613158 Review.
Cited by
-
Antileukotrienes and laboratory models of asthma.Clin Rev Allergy Immunol. 1999 Spring-Summer;17(1-2):223-33. doi: 10.1007/BF02737606. Clin Rev Allergy Immunol. 1999. PMID: 10436868 Review. No abstract available.
-
Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease.Mediators Inflamm. 1999;8(3):133-46. doi: 10.1080/09629359990469. Mediators Inflamm. 1999. PMID: 10704051 Free PMC article. Review.
-
Leukotriene activity modulation in asthma.Drugs. 1997 Sep;54(3):369-84. doi: 10.2165/00003495-199754030-00002. Drugs. 1997. PMID: 9279501 Review.
-
Mechanism of glutamine inhibition of cytosolic phospholipase a2 (cPLA2 ): Evidence of physical interaction between glutamine-Induced mitogen-activated protein kinase phosphatase-1 and cPLA2.Clin Exp Immunol. 2015 Jun;180(3):571-80. doi: 10.1111/cei.12585. Epub 2015 Apr 29. Clin Exp Immunol. 2015. PMID: 25599677 Free PMC article.
-
Role of Leukotrienes and Leukotriene Modifiers in Asthma.Pharmaceuticals (Basel). 2010 Jun 2;3(6):1792-1811. doi: 10.3390/ph3061792. Pharmaceuticals (Basel). 2010. PMID: 27713330 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical